Literature DB >> 29035901

CE: Preeclampsia: Current Approaches to Nursing Management.

Cindy M Anderson1, Mandy J Schmella.   

Abstract

: Preeclampsia, one of four hypertensive disorders of pregnancy, has traditionally been characterized as new-onset hypertension and proteinuria developing after 20 weeks' gestation. It is, however, now understood to be a complex, progressive, multisystem disorder with a highly variable presentation and a number of potentially life-threatening complications. The American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy has refined preeclampsia diagnostic criteria accordingly, and as the disorder's pathogenesis has been more clearly defined, new targets for screening, diagnosis, prevention, and treatment have emerged. This clinical update provides a review of current practice related to preeclampsia risk assessment, prediction, and management. It discusses preeclampsia pathophysiology and points readers to valuable health care resources on the topic.

Entities:  

Mesh:

Year:  2017        PMID: 29035901     DOI: 10.1097/01.NAJ.0000526722.26893.b5

Source DB:  PubMed          Journal:  Am J Nurs        ISSN: 0002-936X            Impact factor:   2.220


  3 in total

1.  EZH2 enhances proliferation and migration of trophoblast cell lines by blocking GADD45A-mediated p38/MAPK signaling pathway.

Authors:  Xuefang Qian; Yuying Zhang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  DNA Methylation of Endoglin Pathway Genes in Pregnant Women With and Without Preeclampsia.

Authors:  Allison H Rietze; Yvette P Conley; Dianxu Ren; Cindy M Anderson; James M Roberts; Arun Jeyabalan; Carl A Hubel; Mandy J Schmella
Journal:  Epigenet Insights       Date:  2020-10-09

3.  IL‑1β‑induced pentraxin 3 inhibits the proliferation, invasion and cell cycle of trophoblasts in preeclampsia and is suppressed by IL‑1β antagonists.

Authors:  Xiaoxi Wang; Jing Zhang; Jing Ji
Journal:  Mol Med Rep       Date:  2022-02-09       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.